Brief: Vertex Pharmaceuticals Inc - Authorizes $4 Billion Stock Repurchase Program - SEC Filing
19/05/2025 21:48
Vertex Pharmaceuticals Inc VRTX.O: VERTEX PHARMACEUTICALS INC - AUTHORIZES $4 BILLION STOCK REPURCHASE PROGRAM - SEC FILING Source text: [ID:n0000875320-25-000199] Further company coverage: VRTX.O
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31